Evidence mapPaperPMID 41279516Full record

ArticlebioRxiv : the preprint server for biology2025

Protofibril Binding Peptides Recognize and Inhibit Huntingtin Amyloid Formation

Kaori Noridomi, J Mario Isas, Anakha Ajayan, Tristan McPhail, Hui Xu, Anoop Rawat, Christopher Hughes, Natalie Chen, Joshua Lugo, Terry T Takahashi and 3 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kaori NoridomiUCB Pharma, Cambridge, MA 02140.ORCID 0000-0002-4303-7511
J Mario IsasDepartment of Physiology & Neuroscience, USC Keck School of Medicine, Los Angeles, CA 90033.ORCID 0009-0007-8784-0684
Anakha AjayanDepartment of Physiology & Neuroscience, USC Keck School of Medicine, Los Angeles, CA 90033.ORCID 0009-0008-6605-5457
Tristan McPhailMork Family Department of Chemical Engineering and Materials Science, USC Viterbi School of Engineering, Los Angeles CA 90089.ORCID 0009-0006-7535-7831
Hui XuDepartment of Physiology & Neuroscience, USC Keck School of Medicine, Los Angeles, CA 90033.ORCID 0000-0002-6190-0040
Anoop RawatDepartment of Physiology & Neuroscience, USC Keck School of Medicine, Los Angeles, CA 90033.ORCID 0000-0002-5838-0275
Christopher HughesMork Family Department of Chemical Engineering and Materials Science, USC Viterbi School of Engineering, Los Angeles CA 90089.ORCID 0009-0002-6919-3384
Natalie ChenDepartment of Physiology & Neuroscience, USC Keck School of Medicine, Los Angeles, CA 90033.ORCID 0000-0001-9706-6679
Joshua LugoDepartment of Physiology & Neuroscience, USC Keck School of Medicine, Los Angeles, CA 90033.ORCID 0009-0009-6906-2537
Terry T TakahashiDepartment of Chemistry, USC Dornsife College of Letters Arts and Sciences, Los Angeles, CA 90089.ORCID 0000-0002-6835-242X
Jeannie ChenDepartment of Physiology & Neuroscience, USC Keck School of Medicine, Los Angeles, CA 90033.ORCID 0000-0002-7904-9629
Ralf LangenDepartment of Physiology & Neuroscience, USC Keck School of Medicine, Los Angeles, CA 90033.ORCID 0000-0003-2816-6531
Richard W RobertsMork Family Department of Chemical Engineering and Materials Science, USC Viterbi School of Engineering, Los Angeles CA 90089.ORCID 0000-0002-8587-5097

Funding

Phototransduction in health and diseaseR01EY012155 · NEI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Jeannie Chen · 1998 to 2026
$11.8M
Ophthalmic Therapeutics Engineering CoreP30EY029220 · NEI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Mahnaz Shahidi · 2018 to 2026
$6.5M
Genetically Encoded Probes of Huntingtin MisfoldingR01NS125769 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Jeannie Chen, Ralf Langen · 2022 to 2026
$3.2M
NEI NIH HHS P30 EY029220NEI NIH HHS R01 EY012155NINDS NIH HHS R01 NS125769
6 · The paper itself

Abstract

In Huntingtons disease, polyglutamine expansion in huntingtin exon 1 (Httex1) results in stepwise misfolding, amyloid formation, and neuronal death. Here we used mRNA display directed evolution to generate peptide ligands targeting Httex1 protofibrils, an early, toxic misfolding intermediate. Two distinct peptide families bind protofibrils, one tryptophan rich and the other glutamine rich, resulting in two predominant peptides HD1 (W-rich) and HD8 (Q-rich). Both peptides bind with high affinity and specificity to the misfolded polyQ structure present in protofibrils, a toxic component that is not recognized by existing huntingtin-directed antibodies. Homo- and heterodimers of HD1 and HD8 bind protofibrils with antibody-like affinity, and potently inhibit aggregation of recombinant and cellular Httex1. The HD8-1 heterodimer can be used like an antibody for immunocytochemistry to identify Httex1 aggregates in transfected cells and in the retina of a Huntingtons disease mouse model system (R6/1). Peptide binding to both

Indexed as

AmyloidHuntington’s DiseaseMajor = BiochemistryMinor = NeurosciencemRNA displaypoly glutamine

Identifiers

PMID41279516
PMCPMC12633338

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.